The World Health Organization (WHO) conducts inspections through its Inspection Services, primarily in connection with the assessment and ongoing oversight of products submitted to its Prequalification Programme. A separate mechanism, the WHO Certification Scheme, does not mean that WHO itself issues GMP certificates: the relevant documents are issued by competent national authorities using WHO-recommended formats.
Scope of WHO prequalification and GMP inspections
This article focuses primarily on human medicines and active pharmaceutical ingredients (APIs) within the WHO Prequalification Programme. Other product streams, including vaccines and in vitro diagnostics (IVDs), are mentioned where their inspection arrangements differ.
Three mechanisms should be distinguished: WHO Prequalification, which assesses specific products; WHO Inspection Services, which conducts or coordinates inspections associated with that assessment and subsequent oversight; and the WHO Certification Scheme, under which national authorities issue documents in formats recommended by WHO. These mechanisms have different purposes and are not interchangeable.
WHO GMP requirements for pharmaceutical manufacturing
WHO prequalification inspections assess compliance with the standards and norms applicable to the relevant product category. For medicines and APIs, the principal reference is WHO Good Manufacturing Practices (GMP), published in the WHO Technical Report Series (TRS).
The inspection scope is linked to the products submitted for prequalification. WHO states that inspections of API and finished pharmaceutical product (FPP) manufacturing sites are restricted to GMP compliance relevant to the products under assessment. Inspections are conducted as sampling exercises: not every element of WHO GMP or every part of a site is necessarily examined.
Other product streams follow their own technical requirements. Vaccine inspections assess compliance with relevant WHO recommendations for production and quality control. IVDs and vector control products are assessed under their respective technical and quality frameworks. Manufacturers should therefore establish which product stream and standards apply before preparing for an inspection.
Who conducts WHO inspections?
Inspections are coordinated and conducted by WHO Inspection Services, a team of expert inspectors supported by a secretariat. WHO may use its own inspection resources or rely on relevant inspection outputs from national medicines regulatory authorities that operate to standards and levels of stringency equivalent to those of WHO Prequalification.
The inspection scope for medicines may include:
- Active pharmaceutical ingredient (API) manufacturing sites.
- Finished pharmaceutical product (FPP) manufacturing sites.
- Contract research organisations (CROs) responsible for relevant clinical, bioequivalence or bioanalytical studies.
- Quality control laboratories (QCLs).
Initial manufacturing-site inspections are associated with the assessment of products submitted for prequalification. Inspection activities may also include follow-up, routine surveillance and special inspections during the product’s prequalification lifecycle.
Types of WHO GMP inspections
Initial inspection
An initial inspection is conducted as part of the assessment of a product submitted for prequalification. Its purpose is to establish whether the relevant manufacturing site complies with WHO GMP requirements. The inspection may also examine the consistency of information in the product dossier with actual manufacturing operations, including relevant records and data.
Follow-up inspection
A follow-up inspection verifies whether the manufacturer has adequately implemented the corrective and preventive actions (CAPA) proposed in response to previous inspection findings. It may be required where written CAPA responses are insufficient or where the nature of the observations warrants on-site verification.
Routine surveillance inspection
Routine surveillance inspections verify that manufacturing sites continue to comply with applicable WHO requirements after prequalification. Their frequency and scope are determined using a risk-based approach, taking account of the site’s compliance history, operational complexity and other relevant factors.
Special (for-cause) inspection
A special inspection is initiated in response to a specific concern, such as an alert, complaint or other information indicating a potential compliance problem. Its scope is focused on the circumstances that triggered the inspection.
Desk assessment and inspection waivers
For API and FPP manufacturing sites, WHO may waive or defer an on-site inspection where satisfactory, recent, relevant and reliable evidence of compliance is available. A waiver may be considered where an equivalent national medicines regulatory authority has conducted an inspection within the previous two years and declared a positive outcome. WHO then reviews the inspection report, its scope and relevance to the product under assessment, the implementation of any CAPAs and other supporting documentation before deciding whether an on-site inspection can be waived in whole or in part.
In exceptional circumstances, WHO may also consider a distant assessment based on quality risk management principles and the use of information technology, where an on-site inspection or desk assessment cannot be performed.
How does a WHO inspection work?
For the relevant initial inspection pathway for API and FPP manufacturing sites, WHO publishes indicative procedural timelines. These include scheduling within six months of dossier acceptance for assessment, notification generally one to two months before the inspection, an inspection report within 30 days of the last day of the inspection, and submission of proposed CAPAs within 30 days of the relevant request. No more than two CAPA rounds are normally allowed.
WHO reviews the proposed CAPAs. A follow-up inspection may be conducted within six months of the last day of the previous inspection if written responses are inadequate, particularly where critical observations were identified. These are pathway-specific procedural timelines, not a guarantee that every WHO inspection will follow an identical schedule.
Before the inspection, WHO reviews the site master file and relevant sections of the product dossier. The manufacturer receives information about the inspection and its planned scope. The inspection may involve reviewing documents and records, observing manufacturing operations, interviewing personnel and verifying relevant information.
Inspectors collect evidence of compliance and non-compliance. Statements of fact are discussed and verified before observations are finalised. The report lists the observations and findings identified during the inspection, after which the manufacturer is expected to investigate the underlying issues and submit an appropriate CAPA response.
How are inspection findings classified?
WHO classifies inspection observations into three principal categories:
- critical — observations involving a potential risk of harm to the user.
- major — significant deviations from applicable good practice requirements.
- other — less significant deviations that nevertheless require appropriate attention.
For initial API and FPP manufacturing-site inspections, WHO states that, where no critical observations and fewer than six major observations are identified, the inspection can normally be closed following acceptance of the proposed CAPAs. Where critical observations or a larger number of major observations are identified, additional scrutiny may be required, including a follow-up inspection. Other observations are generally verified during the next routine inspection.
A positive outcome may be documented in a WHO Public Inspection Report (WHOPIR). A WHOPIR is a publicly available summary of an on-site inspection report or desk assessment, indicating that the site or study was found compliant with the relevant international standards and norms and consistent with the dossier information. Publication is subject to the agreement of the manufacturer, CRO or laboratory. A WHOPIR does not itself constitute prequalification of a site or product; product prequalification is indicated by inclusion in the relevant WHO list.
WHO prequalification is granted to a product, not to a manufacturing site as an independent entity. The product is included in the WHO list together with its specified manufacturing sites.
WHO Notice of Concern: when manufacturers fail to resolve findings
Where significant non-compliances remain unresolved, WHO may issue a Notice of Concern (NOC). A Notice of Concern is a public notification issued when a manufacturer, CRO or medicines quality control laboratory fails to resolve significant inspection findings and implement an appropriate CAPA plan, potentially affecting the safety, efficacy or quality of a prequalified product or the validity of laboratory results.
A Notice of Concern is not necessarily cause for public health alarm. Depending on the findings and identified risks, WHO may take additional measures, including suspension of products from the WHO List of Prequalified Products, suspension of a prequalified quality control laboratory, a compulsory variation to temporarily or permanently suspend a manufacturing site, recall of affected batches or products, or rejection of new prequalification applications.
The notice remains published until WHO is satisfied that an adequate CAPA plan has been implemented effectively. A Notice of Concern should not automatically be interpreted as a product recall or a declaration of an immediate public health emergency; the consequences depend on the findings, associated risks and measures taken by WHO.
Prequalification also creates continuing obligations for manufacturers. These include maintaining compliance, reporting relevant changes, submitting required information and responding to quality-related issues throughout the product lifecycle. Inclusion in the WHO list does not represent a permanent guarantee of compliance.
The “WHO certificate”: what does it actually mean?
WHO does not issue GMP certificates to manufacturing sites under its Certification Scheme. The WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce is a voluntary international mechanism intended to provide assurance to participating countries about the quality of pharmaceutical products moving in international commerce. Its principal document is the Certificate of a Pharmaceutical Product (CPP).
Under the Scheme, the competent authority in the exporting country issues the certificate using the format recommended by WHO. The document provides information about the product’s licensing status, manufacturer and relevant GMP compliance information. The issuing national authority is responsible for the information contained in the certificate.
The model CPP states that the certificate conforms to the format recommended by WHO. It is not a WHO-issued certificate and should not be presented as WHO certification of the manufacturing site.
When a manufacturer states that its site has been inspected or certified under WHO GMP requirements, it is therefore important to establish which national authority conducted the inspection and issued the relevant document. A national GMP certificate or CPP issued under the WHO Certification Scheme is not equivalent to a WHO Prequalification inspection or a product’s inclusion in the WHO List of Prequalified Medicinal Products. The mechanisms serve different regulatory purposes and neither automatically replaces the other.
Recognition mechanisms: GBT, WLA and CRP
Global Benchmarking Tool (GBT)
The WHO Global Benchmarking Tool is the principal instrument used to evaluate national regulatory systems for medical products. It assesses the regulatory framework, institutional capabilities and the performance of regulatory functions. Regulatory systems are evaluated against maturity levels from ML1 to ML4. GBT evaluates national regulatory authorities and regulatory systems, not individual pharmaceutical manufacturers or production facilities.
WHO Listed Authorities (WLA)
The WHO Listed Authorities framework provides a mechanism for evaluating and publicly recognising regulatory authorities operating at an advanced level of performance. Designation requires an appropriate level of maturity under GBT and a separate performance evaluation. The transitional WLA arrangement remains valid until 31 March 2027; inclusion on the transitional list does not itself confer permanent WLA status.
For manufacturers, WLA recognition can be relevant indirectly because WHO and other authorities may rely on regulatory work and inspection outputs from recognised authorities, reducing unnecessary duplication.
Collaborative Registration Procedure (CRP)
The WHO Collaborative Registration Procedure is a regulatory reliance mechanism designed to facilitate and accelerate national registration of medical products. Participating national regulatory authorities can access WHO Prequalification assessment reports, including relevant inspection information, to support their own regulatory decisions.
WHO states that the aim is for participating authorities to issue a regulatory decision within 90 working days. Participation is voluntary, and the national authority retains responsibility for its final registration decision. CRP does not replace national marketing authorisation requirements.
What should manufacturers establish before a WHO inspection?
Manufacturers preparing for WHO Prequalification inspection should clarify the following points:
- Regulatory pathway: whether the site is involved in an application for WHO prequalification or whether the inspection is part of ongoing surveillance or a specific follow-up process
- Inspection type: whether the planned activity is an initial, routine surveillance, follow-up or special inspection.
- Applicable standards: whether the inspection concerns a medicine, API, vaccine, IVD or another product stream, and which WHO requirements apply
- Previous inspection history: whether an equivalent national regulatory authority has recently inspected the site and whether the report could support a request for desk assessment
- CAPA readiness: whether the manufacturer can identify root causes, demonstrate effective corrective actions and provide reliable supporting evidence
- Findings classification: whether the quality team understands the distinction between critical, major and other observations and the implications for inspection closure
- Public reporting and regulatory consequences: whether the organisation is prepared for publication of a WHOPIR or, where significant non-compliances remain unresolved, a Notice of Concern
- Post-prequalification responsibilities: who is responsible for change notifications, product quality issues and ongoing communication with WHO
Understanding these distinctions helps manufacturers prepare for the correct regulatory process and avoid confusing WHO Prequalification inspections with national GMP certification or broader regulatory recognition mechanisms.
The next article in the series: “Japan: PMDA and MHLW — a regulatory partnership”.


